deltatrials
Completed PHASE2 NCT00003466

Temozolomide in Treating Patients With Progressive Low-Grade Glioma

Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal

Sponsor: Duke University

Conditions Brain and Central Nervous System Tumors
Interventions temozolomide
Updated 6 times since 2017 Last updated: Jul 7, 2014 Started: Mar 31, 1998 Primary completion: Jul 31, 2005 Completion: Jul 31, 2005

A PHASE2 clinical study on Brain and Central Nervous System Tumors, this trial is completed. The trial is conducted by Duke University and has accumulated 6 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Duke University
  • National Cancer Institute (NCI)
Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Durham, United States
  • • Philadelphia, United States